Targeted and Untargeted Urinary Metabolic Profiling of Bladder Cancer

May 2023

Authors: MD, FEBU Anna Ossolińska, MD, PhD, FEBU Tadeusz Ossolinski, MD, PhD, FEBU Krzysztof Ossoliński, Tomasz Ruman 2, Valérie Copié 3, Brian P Tripet 3, Artur Kołodziej 4, Aneta Płaza-Altamer 4, Anna Nieczaj 2, Joanna Nizioł 5

Abstract

This study evaluated polar metabolite profiles in urine samples from 100 bladder cancer (BC) patients and 100 normal control (NC) subjects using nuclear magnetic resonance (NMR) and high‑resolution nanoparticle-based laser desorption/ionization mass spectrometry (LDI‑MS).

  • Identified: Five potential urine biomarkers via NMR; 25 LDI‑MS detected compounds (peptides & lipids) distinguishing BC from NC.
  • Discriminatory ability: Metabolite level variations correlated with tumor stage and grade.
  • Results: Receiver Operating Characteristic (ROC) analysis showed AUC > 0.87 for all metabolomic platforms.
  • Conclusion: These metabolites represent promising non-invasive biomarkers for detection and staging of bladder cancer

Full link below